Itraconazole | Rumikoz capsules 100 mg, 15 pcs.

Latin name

Rumycoz



packaging 15 pcs

Pharmacological action

Rumikoz - a wide spectrum antifungal.

Pharmacodynamics

Synthetic broad-spectrum antifungal agent derived from triazole.

inhibits ergosterol synthesis, which is an important component of the cell membrane of fungi.

Active against dermatophytes (Trichophyton spp., Microsporum spp., Epidermophyton floccosum), yeast-like fungi and yeast (Cryptococcus neoformans, Pityrosporum spp., Trichosporon spp., Geotrichum spp., Candida sppa., C. glida b. spp. and C. krusei), Aspergillus spp., Histoplasma spp., Paracoccidioides brasiliensis, Sporothrix schenckii, Fonsecaea spp., Cladosporium spp., Blastomyces dermatitidis, Pseudallescheria boydii, Penicillium marneffei, and other yeast fungi.

Pharmacokinetics

Absorption

When administered orally, the maximum bioavailability of itraconazole is observed when capsules are taken immediately after meals. Tmax in plasma - 3-4 hours after ingestion.

The distribution of

Css of itraconazole in plasma 3-4 hours after taking the drug is 0.4 μg / ml (when taking 100 mg 1 time per day), 1.1 μg / ml (when taking 200 mg 1 time per day) and 2 μg / ml (when taken 200 mg 2 times a day). With prolonged use, Css is achieved within 1-2 weeks. Plasma protein binding is 99.8%.

Itraconazole penetrates well and is distributed in tissues and organs. The concentration of the drug in the lungs, kidneys, liver, spleen, bones, stomach, skeletal muscle is 2-3 times higher than the corresponding plasma concentration. The accumulation of the drug in keratin tissues, especially in the skin, is about 4 times higher than the accumulation in plasma, and the rate of excretion depends on the rate of epidermal regeneration. Unlike plasma concentration, which is not detectable within 7 days after discontinuation of therapy, therapeutic concentration in the skin persists for 2-4 weeks after the termination of the 4-week course of treatment in the vaginal mucosa - within 2 days after the completion of the 3-day course of treatment at a dose of 200 mg once a day and for 3 days after the end of 1 -day course of treatment at a dose of 200 mg 2 times a day. The therapeutic concentration of the drug in nail keratin is determined 1 week after the start of treatment and persists for 6 months after completion of a 3-month course of therapy. Itraconazole is also determined in the secretion of the sebaceous and sweat glands.

Metabolism

Metabolized in the liver with the formation of active metabolites, one of which - hydroxyitraconazole - has an antifungal effect comparable to that of itraconazole in vitro.

Excretion

Excretion from plasma is biphasic with a final T1 / 2 of 24–36 hours.

Excretion with feces is from 3 to 18% of the dose, kidneys - less than 0.03% of the dose, approximately 35% of the dose is excreted in the form of metabolites in the urine for 1 week.

Pharmacokinetics in special clinical cases

In patients with renal failure, as well as some patients with impaired immunity (eg AIDS, after organ transplantation, neutropenia), the bioavailability of itraconazole may be reduced. In patients with cirrhosis, the bioavailability of itraconazole is reduced, T1 / 2 is increased.

Indications

dermatomycosis

fungal keratitis

onychomycosis caused by dermatophytes and / or yeast and mold

systemic mycoses: systemic aspergillosis and candidiasis

cryptococcosis cryptococcosis cryptococcosis if first-line drugs are not applicable in this case or are not effective)

histoplasmosis

sporotrichosis

paracoccidioidomycosis

blastomycosis

other systemic or tropical mycoses

candidiasis with lesions of the skin and mucous membranes, including vulvovaginal candidiasis

deep visceral candidiasis

pityriasis versicolor.

Pregnancy and lactation

Composition

1 capsule contains:

Active ingredient:

itraconazole 100 mg

Excipients:

hypromellose poloxamer (lutrol)

wheat starch

sucrose.

Dosage and administration

Dosage regimen is individual.

Side effects of

From the gastrointestinal tract: dyspepsia, nausea, vomiting, decreased appetite, abdominal pain, diarrhea, constipation.

From the hepatobiliary system: a reversible increase in the activity of hepatic transaminases, hepatitis is very rare - severe toxic damage to the liver, including acute fatal liver failure.

From the nervous system: headache, dizziness, peripheral neuropathy.

Allergic reactions: skin rash, pruritus, urticaria, angioedema, rarely erythema multiforme exudative (Stevens-Johnson syndrome).

From the skin: alopecia, photosensitivity.

Other: menstrual irregularities, hypokalemia, edema syndrome, congestive heart failure and pulmonary edema, hypercreatininemia, staining of urine in a dark color.

Drug interaction

drugs affecting the absorption of itraconazole

Drugs that reduce the acidity of gastric juice reduce the absorption of itraconazole.

drugs affecting the metabolism of itraconazole

Itraconazole is mainly cleaved by the CYP3A4 enzyme. When itraconazole is co-administered with rifampicin, rifabutin, phenytoin, carbamazepine, isoniazid, which are potent inducers of CYP3A4, the bioavailability of itraconazole and hydroxyitraconazole is significantly reduced, leading to a significant decrease in efficacy. Concomitant use of Rumikosa® with these drugs, which are potential inducers of hepatic enzymes, is not recommended.

Powerful CYP3A4 enzyme inhibitors (eg ritonavir, indinavir, clarithromycin, erythromycin) may increase the bioavailability of itraconazole.

Effect of itraconazole on the metabolism of other drugs

Itraconazole may inhibit the metabolism of drugs cleaved by the CYP3A4 enzyme. The result may be an increase or prolongation of their action, including and side effects. After discontinuation of Rumikoz® treatment, the plasma concentration of itraconazole decreases gradually, depending on the dose and duration of treatment (see Pharmacokinetics). This should be taken into account when discussing the inhibitory effect of itraconazole on concomitant drugs.

drugs, which are not recommended at the same time as Rumicosis®

BPC. In addition to the possible pharmacokinetic interaction associated with a common metabolism pathway involving the CYP3A4 enzyme, BCCs can have a negative inotropic effect, which is amplified when co-administered with Rumikoz®.

Preparations for the simultaneous administration of which it is recommended to monitor their plasma concentrations, effects, and side effects. If necessary, the dose of these drugs should be reduced, if necessary:

some immunosuppressive agents (cyclosporine, tacrolimus, sirolimus (also known as rapamycin)

some HMG-CoA reductase inhibitors cleaved by CYP3A4 (atorvastatin)

ekotor e corticosteroids (budesonide, dexamethasone and methylprednisolone)

other drugs: digoxin, carbamazepine, buspirone, alfentanil, alprazolam, brotizolam, midazolam for intravenous administration, rifabutin, ebastine, reboxetine, cilostazol, disopyramide, eletriptan.

No interaction was found between itraconazole, zidovudine and fluvastatin.

The effect of itraconazole on the metabolism of ethinyl estradiol and norethisterone was not noted.

In vitro studies have demonstrated no interaction between itraconazole and drugs such as imipramine, propranolol, diazepam, cimetidine, indomethacin, tolbutamide, and sulfamerazine when bound to plasma proteins.

Overdose

No data available.

Treatment: in case of accidental overdose, gastric lavage should be carried out during the first hour, if necessary, the appointment of activated charcoal.

Itraconazole is not excreted in hemodialysis.

There is no specific antidote for the drug.

Storage conditions

The drug should be stored in a dry, dark place and out of the reach of children at a temperature not exceeding 25 РC.

Shelf suitability

3 Year



pharmacy terms for prescription prdroduct6177pfpf7dff7dpffdff7dff7f47f47f47f47f47f47f47f47f47f47f47f47f47f47f47fdf for pharmacy Ovia pharmacy leave

Prescription

dosage form

dosage form

capsules